Login to Your Account



Sinopharm to undergo ownership reform in pilot SASAC program

By Kristine Yang
Staff Writer

Wednesday, July 23, 2014

HONG KONG – Sinopharm Group, one of the largest biotech companies in China, is likely to undergo major structural reforms as the government kicks off a series of reforms on its state-owned enterprises (SOEs).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription